International Journal of Cardiovascular Research & Innovation

ABSTRACT

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, prompting the search for novel and targeted therapies. RNA-based therapeutics, particularly small interfering RNA (siRNA) and messenger RNA (mRNA) technologies, have emerged as promising tools in the post-COVID era, offering precise gene-level modulation. siRNA molecules are being explored for silencing atherogenic genes like PCSK9 and ANGPTL3, while mRNA platforms are being investigated for regenerative protein delivery, such as VEGF, to promote angiogenesis in ischemic tissues. This review highlights recent advances in RNA therapeutics for cardiovascular disorders, focusing on molecular targets, delivery challenges, and current clinical progress. It also discusses the role of lipid nanoparticles (LNPs) and other biotech-derived carriers in enhancing RNA stability and specificity. As RNA therapies move beyond infectious diseases, their potential in cardiovascular medicine is gaining rapid attention, paving the way for precision cardiology. Future integration with genomics and personalized medicine is expected to refine therapeutic outcomes further. With continued innovation, RNA platforms may soon complement or even replace traditional cardiovascular interventions.

Article History

Received 1 April 2025; Revised 21 April 2025; Accepted 25 April 2025

KEYWORDS

1. RNA therapeutics
2. Cardiovascular disease
3. siRNA
4. mRNA therapy
5. Lipid nanoparticles (LNPs)